Outcome evaluation of an intervention to improve the effective and safe use of meropenem
| Autor: | Hiromi Higaki, Mitsuhiko Miyamura, Megumi Nakai, Masafumi Okazaki, Yusuke Yagi, Ayumu Hirata |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Pharmaceutical Science Renal function Pharmacy Kidney Function Tests Toxicology Meropenem Drug Administration Schedule Group B Anti-Infective Agents Japan Pharmacokinetics Internal medicine Intervention (counseling) medicine Humans Pharmacology (medical) Adverse effect Aged Aged 80 and over Pharmacology business.industry Drug Administration Routes Middle Aged Surgery Female Thienamycins Patient Safety Liver function Pharmacy Service Hospital business medicine.drug |
| Zdroj: | International Journal of Clinical Pharmacy. 36:648-656 |
| ISSN: | 2210-7711 2210-7703 |
| Popis: | Background Pharmacists have been involved in promoting the proper and safe use of antimicrobial drugs in our institution since 2010. Setting Kochi Medical School Hospital, Japan. Objective To design and evaluate a plan of administration of meropenem (MEPM) based on its pharmacokinetics and pharmacodynamics, drug sensitivity, bacterial cultures, patient condition and renal function. Method A total of 547 patients admitted between April 2010 and March 2013 with serious infections who were successfully treated with MEPM for three or more days were analysed. Patients were initially divided into two groups according to renal function: group A consisted of patients with mild renal dysfunction [creatinine clearance (CLcr) > 50 mL/min] while group B consisted of patients with moderate to severe renal dysfunction (CLcr ≤ 50 mL/min). These groups were then subdivided into two groups according to the implementation of pharmacist intervention. Main outcome measures Daily dose, frequency of administration, dose interval, duration of therapy, adverse events and cost reduction. Results In the non-intervention subgroup within group A, the daily dose was 1,000 mg/day, the frequency of administration was 1.8 ± 0.6 times/day, and the duration of therapy was 9.4 ± 5.4 days. In the intervention subgroup within group A, the daily dose was 1,500 mg/day, the administration frequency was 2.5 ± 0.6 times/day, and the duration of therapy was 7.4 ± 3.7 days. Although the dose was higher (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink